Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Nerac IPDex™
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / The Road to IVDR Implementation

The Road to IVDR Implementation

Facebook0
Google+0
LinkedIn0
Twitter0

Dramatic changes to the regulatory landscape for in vitro diagnostic (IVD) medical devices are in the making. Some of the most impactful changes include a new classification of IVDs, an expansion of post market surveillance and the increased need for Notified Body review. Most medical device manufacturers are aware that failure to meet In Vitro Diagnostic Regulation (IVDR) 2017/746 deadlines can result in either failure to obtain a CE marking or loss of a currently valid CE mark. The deadlines, however, are not written in stone.

This article takes a closer look at the revised IVDR implementation timeline and potential impacts on certification.  Access the article here.

The article is free!

Simply fill in the form below, verify your email address
and you’ll be sent a link to download the article.
Please wait...
Loader

Related Posts

  • The European In Vitro Diagnostic Regulation: Performance Evaluation
    54
    By Erica Kramer, Ph.D., Senior Nerac Analyst/Medical Writer Originally Published: June 30, 2020 In May 2017, the European Parliament and Council published Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), repealing Directive 98/79/EC (IVDD). The new regulation will apply starting May 26, 2022. Unlike under the IVDD, which allowed for self-certification for many…
    Tags: ivdr, manufacturers, published, devices, regulation, vitro, increased, diagnostic, nerac, article
  • Understanding CFDA Expectations Regarding Clinical Literature Evaluation for Medical Devices under Order 650: A Nerac Perspective
    47
    By Richard Conforti, M.S., Nerac Analyst, Originally Published: April 19, 2016 In 2014 the Chinese Food and Drug Administration, CFDA, updated their regulations on medical devices. These updates substantially changed the way in which a medical device company, particularly international companies not based or founded in China, registers their devices in China. In part 1…
    Tags: nerac, devices, medical, originally, published, m.s, changes, article, market, device
  • Clinical Literature Evaluations via an Objective Third Party Reviewer: Maintaining Compliance with the EU Medical Directives and Beyond
    47
    By Ron Sills, Nerac Analyst, and Donna Mitchell-Magaldi, Nerac Analyst Originally Published: September 26th, 2014 In 2009, the European Commission released MedDev 2.7.1 Rev.3 “Clinical Evaluation: A Guide for Manufacturers and Notified Bodies” as a supplement to the requirements of the EU Medical Device Directive 93/42/EEC.  In order for medical devices to be marketed in…
    Tags: medical, device, ce, notified, compliance, nerac, manufacturers, mark, regulatory, changes
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence conflict minerals Disruptive Technologies energy EU MDR FDA food helga weires Industry 4.0 innovation Inspiring Next intellectual property IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation patenting patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting Tech Scouting XcellR8
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities
  • Privacy Policy

Copyright © 2023 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!

  • This field is for validation purposes and should be left unchanged.